A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

The company is developing generative AI methods to design proteins from scratch, with applications in drug discovery and ...

Backed by influencial names in the life sciences industry, Latent Labs offers an AI platform to accelerate and improve drug ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Latent Labs, the company building AI foundation models to make biology programmable, today emerged from stealth with $50M in total funding to accelerate their progress and partnerships.

The risk of pharma bribery, the risk of brain drain, and other risks (and rewards) in the biotech landscape this week.

The company has assembled a team that hails from DeepMind and Microsoft, AI in drug discovery specialist Exscientia, genomics and machine learning company Zymergen (bought by Ginkgo Bioworks in 2022), ...

Former DeepMind employees raise $40 million to launch London-based startup 'laser-focused' on AI protein design.

The fundraising was co-led by Radical Ventures, which specialises in AI software companies, and European healthcare venture firm Sofinnova Partners. Other investors include Jeff Dean, Google’s chief ...